Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Marginal Zone Lymphoma
NCT03322865Phase 2Active, not recruiting
- Start
- Nov 2018
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in marginal zone lymphoma (MZL). Started Nov 2018; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03322865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03322865.